Resumen de Difficulties on the access to innovative targeted therapies for lung cancer in Spain

V. Calvo de Juan, Carlos Camps Herrero, Enric Carcereny Costa, Manuel Cobo Dols, Manuel Dómine Gómez, María Rosario García Campelo, José Luis González Larriba, María Guirado, Florentino Hernando Trancho, Bartomeu Massuti Sureda, E. Nadal, Delvys Rodríguez Abreu, A. Sánchez, Ivana Sullivan, Mariano Provencio Pulla

• Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain.

  Methods Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments.

  Results More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System.

  Conclusion SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.